Better Pharma ETF: iShares IHE vs. State Street XPH

IHE returned 40.8% over the trailing year and grew $1,000 to $1,759 over five years, versus XPH’s 36.2% and $1,453, respectively. IHE is more concentrated, with Eli Lilly and Johnson & Johnson together accounting for 45.91% of holdings, and yields 1.4%; XPH’s equal-weighted approach has a 0.4% yield, a lower 0.35% expense ratio, and a deeper five-year maximum drawdown of 34.9% versus IHE’s 16.0%. The article presents the choice as dependent on investors’ existing exposure and portfolio objectives.

Analysis

The portfolio choice is less “diversified versus concentrated” than large-cap quality exposure versus a material small- and mid-cap selection effect. XPH’s equal-weight design reduces single-name dependence, but can increase sensitivity to financing conditions, clinical or product setbacks, and thinner trading in smaller constituents. IHE’s weight in Eli Lilly and Johnson & Johnson makes it a concentrated bet on those companies’ execution; that concentration may also have insulated its reported five-year drawdown relative to XPH. Do not extrapolate that historical difference as a stable risk ranking: index composition, measurement window, and rebalancing matter.

The contrarian point is that XPH’s broader name count may overstate diversification, while IHE’s concentration may be desirable for investors seeking liquid large-cap exposure. Conversely, investors with existing Lilly or J&J exposure could be adding substantial overlap through IHE. The yield gap is not a reliable valuation signal; verify distribution composition and current holdings before treating it as income advantage. The expense-ratio difference is unlikely to drive near-term relative performance.

There is no clear catalyst in this comparison alone. Over days, ETF flows and constituent news dominate; over 1–3 months, earnings and guidance from the largest weights can drive IHE relative returns, while smaller constituents make XPH more exposed to company-specific surprises. Over 6–18 months, reassess whether equal-weight rebalancing and smaller-company exposure are being rewarded. The thesis weakens if updated holdings show materially changed concentration, or if relative performance is explained by temporary constituent events rather than portfolio structure.

Key Decisions for Investors

• Avoid a directional ETF trade based on the trailing return or maximum-drawdown figures alone; first verify the data’s dates, index methodologies, current holdings, and fund liquidity.
• For a relative-value expression, consider a modest long IHE / short XPH position only when seeking large-cap pharma exposure against smaller-company exposure; size to tolerate Lilly and J&J concentration, and define an exit around a material change in holdings or a reversal in relative performance.
• If already long Lilly or Johnson & Johnson, review aggregate look-through exposure before adding IHE; XPH may diversify issuer weights, but it is not a low-risk substitute given its smaller constituents.
• Treat XPH’s lower stated fee and IHE’s higher trailing yield as secondary selection factors; monitor tracking, bid-ask spreads, distribution details, and the next holdings update before acting.